AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2582711 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 6.25 mg/hr continuous infusion
Number of subjects: 15
Study 2582711 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 10 mg/hr continuous infusion
Number of subjects: 15
Study 2582711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 186417 — intervention group
Group type: COMPARATOR
Intervention: Immunotherapy with Pasteur strain BCG, either alone or combined with allogeneic tumor cells.
Number of subjects: 107
Study 186417 — intervention group
Group type: COMPARATOR
Intervention: No immunotherapy (control group).
Number of subjects: 107
Study 186417 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy groups (general).
Number of subjects: 107
Study 186417 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy groups (large-cell anaplastic carcinoma).
Number of subjects: 107
Study 186417 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy groups (small-cell anaplastic carcinoma).
Number of subjects: 107
Study 186417 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte migration inhibition assays with tumor-associated antigens.
Number of subjects: 107
Study 186417 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 M KCl extract of pleural effusion cells from a patient with pulmonary adenocarcinoma.
Number of subjects: 107
Study 186417 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed lymphocyte/tumor interaction to tumor-associated antigens.
Number of subjects: 107
Study 31943189 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 295
Study 31943189 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion Regulation (ER)
Number of subjects: 295
Study 31943189 — intervention group
Group type: COMPARATOR
Intervention: Usual class control
Number of subjects: 295
Study 30902793 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA
Number of subjects: 100
Study 30902793 — intervention group
Group type: EXPERIMENTAL
Intervention: QMix
Number of subjects: 100
Study 30902793 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus
Number of subjects: 100
Study 30902793 — intervention group
Group type: COMPARATOR
Intervention: MTA Fillapex
Number of subjects: 100
Study 30902793 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 100
Study 28505987 — intervention group
Group type: EXPERIMENTAL
Intervention: 2mA anodal tDCS (a-tDCS)
Number of subjects: 11
Study 28505987 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mA anodal tDCS (a-tDCS)
Number of subjects: 11
Study 28505987 — intervention group
Group type: COMPARATOR
Intervention: Sham anodal tDCS (a-tDCS)
Number of subjects: 11
Study 25404229 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60
Study 25404229 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 60
Study 25012726 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg IV before chemotherapy, followed by 24 mg continuous infusion and 8 mg IV once daily for 2 days post-chemotherapy)
Number of subjects: 215
Study 25012726 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 215
Study 25012726 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCB1 3435CC genotype
Number of subjects: 215
Study 21816128 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased left atrial dimension (LAD)
Number of subjects: 286
Study 20095330 — intervention group
Group type: EXPERIMENTAL
Intervention: VitB2 5 mg, VitC 200 mg, GPC capsule 50 mg, once every other day and VitA capsules 25,000 units weekly during sea-voyage
Number of subjects: 50
Study 20095330 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 20095330 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group
Number of subjects: 50
Study 17718872 — intervention group
Group type: EXPERIMENTAL
Intervention: Doula support (n = 229)
Number of subjects: 600
Study 17718872 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n = 265)
Number of subjects: 600
Study 15479324 — intervention group
Group type: EXPERIMENTAL
Intervention: New pulmonary artery catheter
Number of subjects: 25
Study 15479324 — intervention group
Group type: COMPARATOR
Intervention: Transoesophageal echocardiography
Number of subjects: 25
Study 11707638 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day)
Number of subjects: 165
Study 11707638 — intervention group
Group type: EXPERIMENTAL
Intervention: CET/CST
Number of subjects: 165
Study 11707638 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (education and relaxation)
Number of subjects: 165
Study 9141923 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 9487 (1.5-2.0 mg/kg)
Number of subjects: 181
Study 9141923 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 9487 (up to 2.0 mg/kg for adults, up to 1.5 mg/kg for elderly)
Number of subjects: 181
Study 9141923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 7702805 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (200 mmol)
Number of subjects: 14
Study 7702805 — intervention group
Group type: COMPARATOR
Intervention: Low sodium diet (20 mmol)
Number of subjects: 14
Study 7702805 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (20 mmol) with insulin dose of 0.8 mU/min
Number of subjects: 14
Study 3124676 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 10 micrograms.kg-1.h-1 naloxone after a 400 micrograms bolus (group F + N)
Number of subjects: 16
Study 3124676 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose (group F)
Number of subjects: 16
Study 3124676 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (F + N and F)
Number of subjects: 16
Study 29993687 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D deep learning network with randomized connection
Number of subjects: 0
Study 29993687 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional LSTM and 3D convolution
Number of subjects: 0
Study 26930191 — intervention group
Group type: EXPERIMENTAL
Intervention: ADOC group (occupation-based goal setting using the ADOC)
Number of subjects: 44
Study 26930191 — intervention group
Group type: COMPARATOR
Intervention: Control group (impairment-based approach without goal setting tools)
Number of subjects: 44
Study 26930191 — intervention group
Group type: EXPERIMENTAL
Intervention: ADOC group
Number of subjects: 44
Study 24529119 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced salt diet (6 g/day)
Number of subjects: 25
Study 24529119 — intervention group
Group type: COMPARATOR
Intervention: Usual salt diet (9 g/day)
Number of subjects: 25
Study 22527555 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified procedure (group B)
Number of subjects: 72
Study 22527555 — intervention group
Group type: COMPARATOR
Intervention: Traditional technique (group A)
Number of subjects: 72
Study 20676333 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 321
Study 20676333 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A vaccine
Number of subjects: 321
Study 17414241 — intervention group
Group type: EXPERIMENTAL
Intervention: IM aripiprazole 9.75 mg
Number of subjects: 301
Study 17414241 — intervention group
Group type: EXPERIMENTAL
Intervention: IM aripiprazole 15 mg
Number of subjects: 301
Study 17414241 — intervention group
Group type: EXPERIMENTAL
Intervention: IM lorazepam 2 mg
Number of subjects: 301
Study 17414241 — intervention group
Group type: COMPARATOR
Intervention: IM placebo
Number of subjects: 301
Study 17414241 — intervention group
Group type: EXPERIMENTAL
Intervention: All active treatments (IM aripiprazole 9.75 mg, 15 mg, IM lorazepam)
Number of subjects: 301
Study 17414241 — intervention group
Group type: EXPERIMENTAL
Intervention: IM lorazepam
Number of subjects: 301
Study 16305857 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 120
Study 16305857 — intervention group
Group type: COMPARATOR
Intervention: On-pump surgery
Number of subjects: 120
Study 16305857 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal preoperative radiologic findings
Number of subjects: 120
Study 11955846 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma intracoronary radiation therapy (ICRT)
Number of subjects: 416
Study 11955846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study 7883849 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen and progestin replacement (n = 22)
Number of subjects: 48
Study 7883849 — intervention group
Group type: COMPARATOR
Intervention: No replacement (control group, n = 26)
Number of subjects: 48
Study 2649413 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of hyoscine intravenously before acid infusion
Number of subjects: 143
Study 2649413 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hyoscine)
Number of subjects: 143
Study 2649413 — intervention group
Group type: COMPARATOR
Intervention: Non-symptomatic patients (no treatment)
Number of subjects: 143
Study 861131 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 6
Study 861131 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (400 mg)
Number of subjects: 6
Study 861131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31525451 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical debridement with adjunct antimicrobial photodynamic therapy (MD + aPDT)
Number of subjects: 98
Study 31525451 — intervention group
Group type: COMPARATOR
Intervention: Mechanical debridement alone (MD)
Number of subjects: 98
Study 27597661 — intervention group
Group type: EXPERIMENTAL
Intervention: TRUCLEAR INCISOR Plus (TIP)
Number of subjects: 60
Study 27597661 — intervention group
Group type: EXPERIMENTAL
Intervention: MyoSure Classic (MC)
Number of subjects: 60
Study 27597661 — intervention group
Group type: EXPERIMENTAL
Intervention: MyoSure Lite (ML)
Number of subjects: 60
Study 27597661 — intervention group
Group type: EXPERIMENTAL
Intervention: TRUCLEAR ULTRA Plus (TUP)
Number of subjects: 60
Study 27597661 — intervention group
Group type: COMPARATOR
Intervention: MyoSure XL (MXL)
Number of subjects: 60
Study 27782964 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate initiation of antiretroviral therapy (ART)
Number of subjects: 4685
Study 27782964 — intervention group
Group type: COMPARATOR
Intervention: Deferred initiation of antiretroviral therapy (ART)
Number of subjects: 4685
Study 23298345 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovariectomy (n = 8)
Number of subjects: 16
Study 23298345 — intervention group
Group type: EXPERIMENTAL
Intervention: Salpingectomy (n = 8)
Number of subjects: 16
Study 23298345 — intervention group
Group type: COMPARATOR
Intervention: Salpingectomy
Number of subjects: 16
Study 21991735 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 90
Study 21991735 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine (0.4 mg/kg)
Number of subjects: 90
Study 21991735 — intervention group
Group type: COMPARATOR
Intervention: Control (2 cc normal saline)
Number of subjects: 90
Study 19651824 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte implantation
Number of subjects: 0
Study 17299471 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methionine (0.17 mmol/kg body weight) with oral iron (ferrous sulfate, 13 mumol/kg)
Number of subjects: 5
Study 17299471 — intervention group
Group type: COMPARATOR
Intervention: Oral methionine (0.17 mmol/kg body weight) without oral iron
Number of subjects: 5
Study 15314347 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health education program (daily for 20 minutes for four weeks)
Number of subjects: 67
Study 15314347 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oral health education)
Number of subjects: 67
Study 11607883 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL treatment before surgery (30 mg every 14 days for 3 months, then every 10 days until 6 months)
Number of subjects: 20
Study 11607883 — intervention group
Group type: COMPARATOR
Intervention: Surgery after SRL treatment
Number of subjects: 20
Study 11607883 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL treatment (30 mg every 14 days for 3 months, then every 10 days until 6 months)
Number of subjects: 20
Study 11607883 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery followed by SRL
Number of subjects: 20
Study 11607883 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL treatment before surgery
Number of subjects: 20
Study 9796594 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (20 minutes daily for 1 month)
Number of subjects: 0
Study 9796594 — intervention group
Group type: COMPARATOR
Intervention: Standard topical care only (Control)
Number of subjects: 0
Study 8035026 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine (three doses on days 0, 20, and 112)
Number of subjects: 2360
Study 2493239 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 3137
Study 2493239 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 3137
Study 2493239 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment (control)
Number of subjects: 3137
Study 30383163 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aid fitting methods (NAL‐NL2 and Audiogram+) with broadband loudness balancing
Number of subjects: 14
Study 30383163 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aid fitting methods (NAL‐NL2 and Audiogram+) with narrowband loudness balancing
Number of subjects: 14
Study 30383163 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 14
Study 28741385 — intervention group
Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg
Number of subjects: 148
Study 28741385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 28741385 — intervention group
Group type: EXPERIMENTAL
Intervention: Teneligliptin
Number of subjects: 148
Study 28741385 — intervention group
Group type: COMPARATOR
Intervention: Placebo/teneligliptin
Number of subjects: 148
Study 28741385 — intervention group
Group type: EXPERIMENTAL
Intervention: Teneligliptin/teneligliptin
Number of subjects: 148
Study 24395557 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate 1500 mg
Number of subjects: 605
Study 24395557 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate 800 mg
Number of subjects: 605
Study 24395557 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine and chondroitin combination
Number of subjects: 605
Study 24395557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 605
Study 23088186 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser (λ=2.78 μm, 20 Hz, pulse duration approximately 140 μs, noncontact mode using a 600‐μm tip) at various power outputs (1.0 W to 4.0 W)
Number of subjects: 140
Study 23088186 — intervention group
Group type: COMPARATOR
Intervention: Control group using conventional technique with burs (G1)
Number of subjects: 140
Study 21654609 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitex agnus castus (VAC)
Number of subjects: 0
Study 21654609 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 0
Study 18614225 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal increments (three layers)
Number of subjects: 4
Study 18614225 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique increments (three layers)
Number of subjects: 4
Study 18614225 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique increments (four layers)
Number of subjects: 4
Study 18614225 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond adhesive
Number of subjects: 4
Study 16490911 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist of 53 common side effects
Number of subjects: 214
Study 16490911 — intervention group
Group type: COMPARATOR
Intervention: Open-ended question
Number of subjects: 214
Study 16490911 — intervention group
Group type: COMPARATOR
Intervention: Open-ended, defined question
Number of subjects: 214
Study 15491533 — intervention group
Group type: COMPARATOR
Intervention: Primary health care
Number of subjects: 560
Study 15491533 — intervention group
Group type: COMPARATOR
Intervention: Pneumology practices
Number of subjects: 560
Study 15491533 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall factors related to HRQL
Number of subjects: 560
Study 11079237 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation through idea exposure via audiotape during brainstorming (Experiments 1 and 2)
Number of subjects: 0
Study 11079237 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation through electronic brainstorming (Experiment 3)
Number of subjects: 0
Study 9286597 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose ingestion (GLU) - 500 ml of glucose polymer solution containing 25 g glucose 15 min before exercise
Number of subjects: 7
Study 9286597 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) - sweet placebo (aspartame)
Number of subjects: 7
Study 9286597 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GLU and CON
Number of subjects: 7
Study 7811540 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to didanosine after prior zidovudine therapy
Number of subjects: 0
Study 7811540 — intervention group
Group type: EXPERIMENTAL
Intervention: High dosages of nevirapine
Number of subjects: 0
Study 7811540 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level resistance to zidovudine
Number of subjects: 0
Study 7811540 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquisition of an HIV strain with high-level resistance to zidovudine
Number of subjects: 0
Study 3217412 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 4 mg/kg
Number of subjects: 12
Study 3217412 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 8 mg/kg
Number of subjects: 12
Study 3217412 — intervention group
Group type: COMPARATOR
Intervention: Triazolam
Number of subjects: 12
Study 3217412 — intervention group
Group type: COMPARATOR
Intervention: Caffeine placebo
Number of subjects: 12
Study 3217412 — intervention group
Group type: COMPARATOR
Intervention: Triazolam placebo
Number of subjects: 12
Study 28882072 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention for postnatal depression
Number of subjects: 0
Study 30343063 — intervention group
Group type: EXPERIMENTAL
Intervention: Bracket debonding with bur roughening
Number of subjects: 70
Study 30343063 — intervention group
Group type: EXPERIMENTAL
Intervention: Bracket debonding with sandblasting
Number of subjects: 70
Study 30343063 — intervention group
Group type: EXPERIMENTAL
Intervention: Polishing after bracket debonding
Number of subjects: 70
Study 30343063 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bracket debonding)
Number of subjects: 70
Study 28746183 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified SMILE procedure (liquid infiltration group)
Number of subjects: 52
Study 28746183 — intervention group
Group type: COMPARATOR
Intervention: Traditional SMILE (control group)
Number of subjects: 52
Study 26232692 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac suppository 2 hours before biopsy + 10 mL of 2% Xylocaine gel 5 minutes before biopsy
Number of subjects: 100
Study 26232692 — intervention group
Group type: COMPARATOR
Intervention: Xylocaine gel only
Number of subjects: 100
Study 23116363 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 900435 8 mg
Number of subjects: 0
Study 23116363 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 900435 12 mg
Number of subjects: 0
Study 23116363 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 900435 20 mg
Number of subjects: 0
Study 23116363 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 900435 30 mg
Number of subjects: 0
Study 23116363 — intervention group
Group type: COMPARATOR
Intervention: Visual effects study
Number of subjects: 0
Study 23116363 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple ascending dose study
Number of subjects: 0
Study 20718311 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-oriented primary health care (CPHC) intervention including fluoride varnish applications, training of primary care workers, and health promotion for oral health at individual, family, and community levels with six-monthly visits over two years.
Number of subjects: 30
Study 20718311 — intervention group
Group type: COMPARATOR
Intervention: Control communities received no intervention, only baseline and two-year follow-up visits.
Number of subjects: 30
Study 18236934 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17154730 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-feedback Intervention to promote Positive Parenting and Sensitive Discipline (VIPP-SD)
Number of subjects: 237
Study 17154730 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 237
Study 14743096 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive conventional weaning (group A)
Number of subjects: 208
Study 14743096 — intervention group
Group type: EXPERIMENTAL
Intervention: Extubation relayed by nasal oxygen therapy (group B)
Number of subjects: 208
Study 14743096 — intervention group
Group type: EXPERIMENTAL
Intervention: Extubation relayed by non-invasive ventilation (NIV) (group C)
Number of subjects: 208
Study 11110676 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy
Number of subjects: 609
Study 11110676 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous transplantation (ABMT)
Number of subjects: 609
Study 11110676 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (alloBMT)
Number of subjects: 609
Study 11110676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytogenetic risk status
Number of subjects: 609
Study 9178382 — intervention group
Group type: EXPERIMENTAL
Intervention: Short version of CPR checklist
Number of subjects: 169
Study 9178382 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer detailed CPR checklist
Number of subjects: 169
Study 9178382 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 169
Study 8252948 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-conserving arterial line system
Number of subjects: 31
Study 8252948 — intervention group
Group type: COMPARATOR
Intervention: Conventional arterial line system
Number of subjects: 31
Study 3531112 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy in hyperbaric oxygen (HBO)
Number of subjects: 104